Evaluation of symptomatic drug effects in Alzheimer’s disease: strategies for prediction of efficacy in humans
Impacto
Scholar |
Otros documentos de la autoría: Deguil, J.; Ravasi, L.; Auffret, A.; Babiloni, Claudio; Bartrés Faz, David; Bragulat, V.; Cassé-Perro, C.; Colavito, V.; Herrero Ezquerro, María Trinidad; Lamberty, Yves; Lanteaume, L.; Pemberton, D.; Pifferi, Fabien; Richardson, Jill C.; Schenker, Esther; Blin, Olivier; Tarragon Cros, Ernesto; Bordet, Regis
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
http://dx.doi.org/10.1016/j.ddtec.2013.03.003 |
Metadatos
Título
Evaluation of symptomatic drug effects in Alzheimer’s disease: strategies for prediction of efficacy in humansAutoría
Fecha de publicación
2013Editor
ElsevierISSN
1740-6749Cita bibliográfica
Drug Discovery Today: Technologies Volume 10, Issue 3, September 2013, Pages e329–e342Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
http://www.sciencedirect.com/science/article/pii/S1740674913000279#Versión
info:eu-repo/semantics/publishedVersionResumen
In chronic diseases such as Alzheimer's disease (AD), the arsenal of biomarkers available to determine the effectiveness of symptomatic treatment is very limited. Interpretation of the results provided in literature ... [+]
In chronic diseases such as Alzheimer's disease (AD), the arsenal of biomarkers available to determine the effectiveness of symptomatic treatment is very limited. Interpretation of the results provided in literature is cumbersome and it becomes difficult to predict their standardization to a larger patient population. Indeed, cognitive assessment alone does not appear to have sufficient predictive value of drug efficacy in early clinical development of AD treatment. In recent years, research has contributed to the emergence of new tools to assess brain activity relying on innovative technologies of imaging and electrophysiology. However, the relevance of the use of these newer markers in treatment response assessment is waiting for validation. This review shows how the early clinical assessment of symptomatic drugs could benefit from the inclusion of suitable pharmacodynamic markers. This review also emphasizes the importance of re-evaluating a step-by-step strategy in drug development. [-]
Publicado en
Drug Discovery Today: Technologies, 2013, Vol. 10, Num. 3Derechos de acceso
Copyright © 2013 Published by Elsevier Ltd.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- MED_Articles [673]